M&A / Deals Curium strikes $8bn deal to buy radiopharma rival Lantheus PharmaphorumTwo players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.Read full story pharminent August 3, 2026 (Last updated: August 8, 2026) Pharmaphorum Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics. Read full story Post navigation Previous: Parsortix study shows promise for ADC target detectionNext: Supernus and Indivior merge to create CNS mega-company with 11 approved drugs Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026